Tolerating False Positives: Amylyx, FDA, And The Legal Case For Broad Regulatory Flexibility

 
• By Sarah Karlin-Smith
  
person stretching while working on desk
Regulatory flexibility was a central theme at Amylyx’s second-chance FDA advisory panel for its ALS drug. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers